Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.2K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.2K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Tumor Progression02:07

Tumor Progression

7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
Cancer02:18

Cancer

55.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RSTG: Robust Generation of High Quality Spatial Transcriptomics Data using Beta Divergence Based AutoEncoder.

IEEE journal of biomedical and health informatics·2026
Same author

Machine Learning and Deep Learning for Neurological Disease Analysis: A Systematic Review Across Five Major Disorders.

Neuroscience·2026
Same author

Optimizing genomics-aware clinical agents in precision oncology.

NPJ systems biology and applications·2026
Same author

Robust feature selection for cancer microarray data using a hybrid mRMR and Binary Lion Optimization Algorithm.

Scientific reports·2026
Same author

The twisted tale of cotranslational protein complex assembly.

Current opinion in structural biology·2026
Same author

Explainable AI-driven diagnosis model for early glaucoma detection using grey-wolf optimized extreme learning machine approach.

PLoS computational biology·2026

Related Experiment Video

Updated: Mar 8, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

7.1K

Integrating Multiple Data Sources for Combinatorial Marker Discovery: A Study in Tumorigenesis.

Sanghamitra Bandyopadhyay, Saurav Mallik

    IEEE/ACM Transactions on Computational Biology and Bioinformatics
    |January 24, 2017
    PubMed
    Summary

    This study introduces a computational framework to identify significant combinatorial markers using gene expression and methylation data. The novel method efficiently finds non-redundant marker combinations, potentially reducing false positives in disease diagnostics.

    More Related Videos

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
    07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    3.0K
    An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
    10:41

    An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

    Published on: April 5, 2018

    10.9K

    Related Experiment Videos

    Last Updated: Mar 8, 2026

    Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
    06:52

    Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

    Published on: July 22, 2020

    7.1K
    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
    07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    3.0K
    An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
    10:41

    An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

    Published on: April 5, 2018

    10.9K

    Area of Science:

    • Bioinformatics and Computational Biology
    • Genomics and Molecular Biology
    • Cancer Research

    Background:

    • Identifying combinatorial markers from diverse data sources like gene expression and methylation is computationally challenging.
    • Existing methods may yield numerous redundant markers, complicating downstream analysis and interpretation.
    • Accurate marker identification is crucial for improving diagnostic and prognostic accuracy in diseases like uterine tumors and prostate carcinoma.

    Purpose of the Study:

    • To develop a novel computational framework for identifying significant combinatorial markers.
    • To integrate gene expression and methylation data effectively for marker discovery.
    • To enhance the efficiency and reduce redundancy in identifying biologically relevant marker sets.

    Main Methods:

    • Integration of gene expression and methylation data into continuous and boolean representations based on their inverse relationship.
    • Introduction of a novel combined score for identifying an initial non-redundant gene set.
    • Application of biclustering and a novel sample-based weighted support for identifying significant, non-redundant gene sets.

    Main Results:

    • The proposed framework successfully identifies significant combinatorial markers from integrated omics data.
    • The method generates a smaller number of significant non-redundant gene sets compared to existing approaches, indicating higher efficiency.
    • Application to uterine tumor and prostate carcinoma data yielded promising sets of combined markers.

    Conclusions:

    • The novel computational framework provides an efficient and effective approach for identifying significant combinatorial markers.
    • The identified combinatorial markers are expected to yield lower false positive rates than individual markers in clinical applications.
    • This approach holds potential for improving diagnostic accuracy and therapeutic strategies in various cancers.